In Brief: Bio-Technology General's BioLon
This article was originally published in The Gray Sheet
Bio-Technology General's BioLon: Firm receives FDA approvable letter Feb. 3 for the 1% sodium hyaluronate viscoelastic lubricant for use in ophthalmic procedures such as cataract removal. The Iselin, New Jersey company says final approval is expected following FDA inspection of the contracted final sterilizer for the product and submission of final labeling...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.